|
Gene: RNF207 |
Gene summary for RNF207 |
Gene summary. |
Gene information | Species | Human | Gene symbol | RNF207 | Gene ID | 388591 |
Gene name | ring finger protein 207 | |
Gene Alias | C1orf188 | |
Cytomap | 1p36.31 | |
Gene Type | protein-coding | GO ID | GO:0001508 | UniProtAcc | Q6ZRF8 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
388591 | RNF207 | C21 | Human | Oral cavity | OSCC | 4.04e-11 | 5.14e-01 | 0.2678 |
388591 | RNF207 | C38 | Human | Oral cavity | OSCC | 5.20e-04 | 5.83e-01 | 0.172 |
388591 | RNF207 | C43 | Human | Oral cavity | OSCC | 1.74e-08 | 1.69e-01 | 0.1704 |
388591 | RNF207 | C46 | Human | Oral cavity | OSCC | 1.52e-23 | 6.29e-01 | 0.1673 |
388591 | RNF207 | C57 | Human | Oral cavity | OSCC | 3.71e-08 | 3.65e-01 | 0.1679 |
388591 | RNF207 | C08 | Human | Oral cavity | OSCC | 1.91e-10 | 1.57e-01 | 0.1919 |
388591 | RNF207 | LN46 | Human | Oral cavity | OSCC | 3.45e-10 | 4.61e-01 | 0.1666 |
388591 | RNF207 | SYSMH2 | Human | Oral cavity | OSCC | 6.92e-04 | 1.55e-01 | 0.2326 |
388591 | RNF207 | SYSMH3 | Human | Oral cavity | OSCC | 4.25e-04 | 1.35e-01 | 0.2442 |
388591 | RNF207 | SYSMH4 | Human | Oral cavity | OSCC | 1.18e-03 | 5.79e-02 | 0.1226 |
388591 | RNF207 | SYSMH5 | Human | Oral cavity | OSCC | 2.74e-03 | 3.43e-02 | 0.0647 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | EOLP: Erosive Oral lichen planus | |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00605629 | Oral cavity | OSCC | epithelial tube morphogenesis | 149/7305 | 325/18723 | 6.73e-03 | 2.50e-02 | 149 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RNF207 | SNV | Missense_Mutation | c.1619C>T | p.Ser540Phe | p.S540F | Q6ZRF8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-60-2698-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | mithramycin | PD | |
RNF207 | deletion | In_Frame_Del | rs781704833 | c.1056_1058delACT | p.Leu356del | p.L356del | Q6ZRF8 | protein_coding | TCGA-77-8009-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
RNF207 | SNV | Missense_Mutation | c.801N>G | p.Ser267Arg | p.S267R | Q6ZRF8 | protein_coding | tolerated(0.32) | possibly_damaging(0.771) | TCGA-EJ-7792-01 | Prostate | prostate adenocarcinoma | Male | <65 | 7 | Unknown | Unknown | SD | |
RNF207 | SNV | Missense_Mutation | c.848N>G | p.Leu283Trp | p.L283W | Q6ZRF8 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-CG-4438-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
RNF207 | SNV | Missense_Mutation | novel | c.1451C>G | p.Ser484Cys | p.S484C | Q6ZRF8 | protein_coding | tolerated(0.07) | benign(0.01) | TCGA-VQ-A8E3-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
RNF207 | SNV | Missense_Mutation | novel | c.1488N>T | p.Trp496Cys | p.W496C | Q6ZRF8 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-E8-A2EA-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |